{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-004639","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.996378+00:00","generated_at":"2026-06-18T23:43:47.203440+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vaxcyte reports Q4 2022 net loss of $78.1M; cash $957.9M; VAX-24 infant IND cleared","bullets":["Net loss of $78.1M for Q4 2022 and $223.5M for full year 2022; R&D expenses $51.6M and $169.5M respectively.","Cash, cash equivalents and investments $957.9M as of Dec 31, 2022, up from $273.1M a year ago.","FDA cleared VAX-24 infant IND; Phase 2 infant study to start Q2 2023; Breakthrough Therapy designation for adults.","Positive Phase 1/2 data for VAX-24 in adults 18-64; Phase 2 study in adults 65+ enrollment completed; topline data expected Q2 2023.","Raised ~$805M in gross proceeds from two follow-on equity offerings in 2022; VAX-31 adult IND expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-004639","json":"https://secwatch.observer/filing/0000950170-23-004639.json","markdown":"https://secwatch.observer/filing/0000950170-23-004639.md","text":"https://secwatch.observer/filing/0000950170-23-004639.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000095017023004639/0000950170-23-004639-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000095017023004639/pcvx-20230227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:43:47.203440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68aea1420c635441daeddc6c6419a1e07b055377","claim":"Vaxcyte, Inc. reported financial results for the quarter and full year ended December 31, 2022.","evidence_excerpt":"On February 27, 2023, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649094/000095017023004639/0000950170-23-004639-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}